PAVmed Inc. (PAVM)

Market Cap	52.54M +353.0%
Revenue (ttm)	71,000 -97.6%
Net Income	-3.77M -99.0%
EPS	-5.63
Shares Out	6.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,606
Open	8.80
Previous Close	9.00
Day's Range	8.31 - 9.11
52-Week Range	6.00 - 28.44
Beta	0.81
Analysts	Strong Buy
Price Target	65.00 (+681.25%)
Earnings Date	May 14, 2026

About PAVM

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 28, 2016
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: PAVM
• Website: https://www.pavmed.com

Analyst Summary

According to one analyst, the rating for PAVM stock is "Strong Buy" and the 12-month stock price target is $65.0.

Price Target

$65.0

(681.25% upside)

Analyst Consensus: Strong Buy